ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2010
Oral bisphosphonate use and breast cancer incidence in postmenopausal women.
Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 7 syntheses or guidelines pooled it, 187 citations in OpenAlex.
- Bisphosphonates and risk of cancers: a systematic review and meta-analysis.British journal of cancer · 2020Pooled it
- Association Use of Bisphosphonates with Risk of Breast Cancer: A Meta-Analysis.BioMed research international · 2020Pooled it
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2019Guideline
- The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies.PloS one · 2015Pooled it
- European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Guideline
- Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.PloS one · 2013Pooled it
- Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Pooled it
- Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.Breast cancer research and treatment · 2020Trial
- Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid.JAMA internal medicine · 2014Trial
- Nitrogen-Based Bisphosphonate Use and Risk of Cancer in Women Aged 50 Years and Older: A National Data Linkage Study.International journal of cancer · 2026Article
- Preventing Bone Loss in Breast Cancer Patients: Designing a Personalized Clinical Pathway in a Large-Volume Research Hospital.Journal of personalized medicine · 2024Article
- Bisphosphonate Use and Breast Cancer Risk among Women with Ductal CarcinomaCancer research · 2021Article
- Association of Antiosteoporotic Medication Bisphosphonates and Denosumab with Primary Breast Cancer: An Electronic Health Record Cohort Study.Women's health reports (New Rochelle, N.Y.) · 2021Article
- Benefits of Bisphosphonate Therapy: Beyond the Skeleton.Current osteoporosis reports · 2020Review
- Bone metastases: a comprehensive review of the literature.Molecular biology reports · 2020Review
- Key steps for effective breast cancer prevention.Nature reviews. Cancer · 2020Review
- The association between adherence with oral bisphosphonates and the risk of breast cancer in post-menopausal women.Journal of bone oncology · 2019Article
- Bisphosphonates and primary breast cancer risk: an updated systematic review and meta-analysis involving 963,995 women.Clinical epidemiology · 2019Article
- The Osteoclast in Bone Metastasis: Player and Target.Cancers · 2018Review
- Oral bisphosphonate use and lung cancer incidence among postmenopausal women.Annals of oncology : official journal of the European Society for Medical Oncology · 2018Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
14 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEmerging clinical evidence suggests intravenous bisphosphonates may inhibit breast cancer while oral bisphosphonates have received limited evaluation regarding breast cancer influence. PATIENTS AND
methodsThe association between oral bisphosphonate use and invasive breast cancer was examined in postmenopausal women enrolled onto the Women's Health Initiative (WHI). We compared a published hip fracture prediction model, which did not incorporate bone mineral density (BMD), with total hip BMD in 10,418 WHI participants who had both determinations. To adjust for potential BMD difference based on bisphosphonate use, the hip fracture prediction score was included in multivariant analyses as a BMD surrogate.
resultsOf the 154,768 participants, 2,816 were oral bisphosphonate users at entry (90% alendronate, 10% etidronate). As calculated hip fracture risk score was significantly associated with both BMD (regression line = 0.79 to 0.0478 log predicted fracture; P < .001; r = 0.43) and breast cancer incidence (P = .03), this variable was incorporated into regression analyses to adjust for BMD difference between users and nonusers of bisphopshonate. After 7.8 mean years of follow-up (standard deviation, 1.7), invasive breast cancer incidence was lower in bisphosphonate users (hazard ratio [HR], 0.68; 95% CI, 0.52 to 0.88; P < .01) as was incidence of estrogen receptor (ER) -positive invasive cancers (HR, 0.70; 95% CI, 0.52 to 0.94, P = .02). A similar but not significant trend was seen for ER-negative invasive cancers. The incidence of ductal carcinoma in situ was higher in bisphosphonate users (HR, 1.58; 95% CI, 1.08 to 2.31; P = .02).
conclusionOral bisphosphonate use was associated with significantly lower invasive breast cancer incidence, suggesting bisphosphonates may have inhibiting effects on breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.